Drug Search Results
More Filters [+]

Relacatib

Alternative Names: relacatib
Latest Update: 2017-10-04
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CTSK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Relacatib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Osteoarthritis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SB-462795/008

P1

Completed

Osteoarthritis

2006-12-15

Recent News Events

Date

Type

Title